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Abstract 26 
The need for new antimicrobial agents is greater than ever because of the emergence of 27 
multidrug resistance in common pathogens and incidence of new infections. Cyclopent-4-ene-28 
1,3-diones (CPDs) have been reported as a new class of compounds with promising 29 
antimicrobial and antifungal properties. Herein we report the selective antibiotic properties of 30 
nostotrebin 6, a phenolic CPD produced biotechnologically by the culture of cyanobacterium 31 
Nostoc sp. str. Lukešová 27/97. High performance countercurrent chromatography (HPCCC) 32 
combined with gel permeation chromatography (GPC) was used for the isolation of 33 
nostotrebin 6 with a relatively high 0.53±0.1% yield (calculated from dried biomass) and final 34 
purity higher than 96 %. Nostotrebin 6 was tested for its antimicrobial and antifungal 35 
activities by using standard micro-dilution method, and the results were expressed as minimal 36 
inhibitory concentrations (MICs). Nostotrebin 6 unequivocally inhibited the growth of Gram-37 
positive reference (Enterococcus faecalis CCM 4224, Staphylococcus aureus CCM 4223 and 38 
Staphylococcus aureus CCM 3953) and multidrug-resistant (Staphylococcus haemolyticus 39 
A/16568, Staphylococcus aureus MRSA 4591 and Enterococcus faecium VanA 419/ana) 40 
strains. Its strongest effect was exerted against the Gram-positive bacteria with MICs ranging 41 
between 6.25 and 15.6 μg/mL. There was no effect on Gram-negative strains tested and 42 
yeasts. Our results suggest that nostotrebin 6 could serve as basic nucleus for further design of 43 
novel antibiotic agents and demonstrate that the bio-production approach based on 44 
HPCCC/GPC isolation endpoint is an efficient methodology for obtaining nostotrebin 6 in 45 
multi-gram scale. Furthermore, the presented isolation method can be easily up-scaled to 46 
process kilograms of the cyanobacterial biomass. 47 
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1. Introduction 51 
Cyclopent-4-ene-1,3-diones (cyclopentenediones, CPDs) represent a relatively newly defined 52 
group of compounds derived from the natural constituents of plants, fungi and bacteria [1]. 53 
This group includes more than 100 chemical individuals, most of them prepared synthetically. 54 
The synthesis of novel CPDs is often devoted to modification of natural CPDs resulting in 55 
structure-activity relationship (SAR) studies and subsequent discoveries of novel bioactives 56 
with applicability in chemical technologies, biotechnology and biomedicine fields. Among 57 
well studied CPD representatives are lucidone and linderone with anti-inflammatory activities 58 
[2-5], cytostatic compound TX-1123  [6], involuton constituent of fungi Paxillus involutus [7-59 
9], madindolines [10-13] and nostotrebin 6 [14-16] attributed to enzyme inhibitory effects. 60 
The novel synthetic approaches are primarily focused on total synthesis of above-mentioned 61 
CPDs and also on strategies for development of structurally simplified CPDs with biological, 62 
especially antibacterial and antifungal activities. This was exampled in the case of 63 
antibacterial coruscanones and their analogues [17-20]. For CPDs, with complex chemical 64 
structure, e.g. nostotrebin 6, the biotechnological production is preferred for preparation of a 65 
suitable amount of the pure compound for biological testing or consequent synthetic 66 
modifications or technological applications. 67 
Nostotrebin 6, i.e. 2,2'-bis[4,5-bis(4-hydroxybenzyl)-2-(4-hydroxyphenyl)cyclopent-4-68 
ene-1,3-dione], is a secondary phenolic metabolite produced by cyanobacterium Nostoc sp. 69 
strain Lukešová 27/97 [16], see Fig. 1. Nostotrebin 6 is an effective inhibitor of 70 
acetylcholinesterase and butyrylcholinesterase [16], and its cytotoxic and pro-apoptotic 71 
properties have been previously reported [15]. Nostotrebin 6 has been obtained from the 72 
cyanobacterial biomass by using conventional separation methods, including solid-phase 73 
extraction and two HPLC steps [16]. However, this multi-step procedure involved time and 74 
solvent consuming operations plus a risk of a loss of compound due to the inevitable 75 
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adsorption effects. High performance countercurrent chromatography (HPCCC) has been 76 
recently used, at a semi-preparative scale, for isolating nostotrebin 6 from Nostoc sp. [21]. 77 
HPCCC is a liquid-liquid partition chromatographic technique, which uses a liquid 78 
stationary phase. Consequently, the method eliminates the complications resulting from the 79 
solid support matrix, such as irreversible adsorptive loss of sample, deactivation and 80 
contamination. HPCCC is cost effective, produces high sample recoveries and permits the 81 
direct introduction of crude extracts into the column without additional sample pre-treatement 82 
[22]. In addition, there is potential for reduced environmental impact of the purification as the 83 
amount of solvents used is low in comparison to classical column chromatography. This 84 
technique has been successfully applied to the separation of a number of drugs, toxins and 85 
natural products [23-26]. Concurrently, the use of HPCCC in combination with gel 86 
permeation chromatography (GPC) on Sephadex LH-20 has been advantageously used for the 87 
isolation and purification of structurally diverse bioactive compounds from complex matrices 88 
derived from plants and cyanobacteria [27-29]. HPCCC is considered orthogonal to GPC 89 
[23], because the retention of the solutes in both techniques is caused by different 90 
mechanisms. This favorable difference renders them complementary chromatographic 91 
techniques, which enables a high level of purification when they are used in combination [30]. 92 
In the present report, nostotrebin 6 was produced via cultivation of Nostoc sp. and 93 
isolated and purified by HPCCC combined with GPC, and tested for its antimicrobial activity 94 
against Gram-positive and Gram-negative strains, including multidrug-resistant Gram-95 
positive bacteria and yeasts. 96 
 97 
98 
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2. Experimental 99 
2.1. Chemicals 100 
All organic solvents used for HPCCC were of HPLC grade and purchased from Fisher 101 
Chemicals (Loughborough, UK). Ammonia was of reagent grade from Fisher Chemicals 102 
(Loughborough, UK). HPCCC water was purified from a Purite Select Fusion pure water 103 
system (Thame, UK).  Organic solvents used for extraction and HPLC analyses were obtained 104 
from Analytika (Prague, Czech Republic). Solutions were prepared using reverse-osmosis 105 
deionized water (Aqua Osmotic, Tišnov, Czech Republic). 106 
 107 
2.2. Cultivation of Nostoc sp. 108 
Cyanobacterial strain Nostoc sp. Lukešová 27/97 (Fig. 1A) was obtained from the culture 109 
collection of soil algae and cyanobacteria of the Institute of Soil Biology of the Academy of 110 
Sciences of the Czech Republic. Maintenance and precultivation of uni-cyanobacterial strain 111 
was carried out on solid Allen & Arnon medium [31] in test tubes. Preparation of the 112 
inoculum for large scale cultivation was performed by strain cultivation in a 250 mL glass 113 
column and subsequent transfer into a 15.0 L photobioreactor containing liquid Allen & 114 
Arnon medium, using a semi-batch system, at the constant temperature of 25 ± 0.5 °C, with 115 
continuous illumination (351 μmol m−1·s−1). The medium was stirred using a flow of mixed 116 
air and CO2 (98:2; v/v). At the end of exponential growth phase the inoculum (10 L) was 117 
transferred into a 100 L bioreactor and cultivated at temperature 25 ± 2 °C, 300 μmol m−1·s−1 118 
and stirred by air enriched with CO2 (98:2; v/v). The batch culture was cultivated for 14 days 119 
and the culture was harvested at the end of the exponential phase as assessed by nitrate 120 
depletion using an ion exchange chromatography system DIONEX ISC-90. It is important to 121 
note that there is only limited knowledge on the chemical composition of the strain Lukešová 122 
27/97, which is a typical member of the genus Nostoc as characterized by vast 123 
   - 6 - 
exopolysaccharide production, especially at the end of the exponential growth phase. In order 124 
to prevent cell lysis and subsequent loss of compound during the stationary phase, the time of 125 
harvest was set to the end of exponential phase as previously reported [16]. The biomass was 126 
harvested by sedimentation, subsequent centrifugation (Sorvall, Thermo Scientific) and 127 
finally freeze-dried prior to extraction. 128 
 129 
2.3. Preparation of the Crude Extract 130 
Freeze-dried biomass of Nostoc sp. Lukešová 27/97 strain was homogenized with sea-sand 131 
and then extracted three times with pure methanol (500 mL per 30 g of biomass). The 132 
resulting methanolic extracts were combined and evaporated to total dryness under reduced 133 
pressure at 40 °C affording the dried material (4 g in total). The dried extract was dissolved in 134 
cold (−20 °C) acetone and stored overnight to precipitate polar lipids [21]. The suspension 135 
obtained was separated from the precipitate by centrifugation (1350 × g, 10 min), and the 136 
precipitation was twice repeated. The supernatant was evaporated until dry and finally stored 137 
in a refrigerator for the subsequent HPCCC separation of nostotrebin 6. A representative 138 
amount of the extract (500 mg) was subjected to HPCCC separation (see below). 139 
 140 
2.4. Separation and Purification Method 141 
2.4.1. High Performance Countercurrent Chromatography (HPCCC) 142 
The separation of nostotrebin 6 by HPCCC was performed on a Midi preparative instrument 143 
(Dynamic Extractions Ltd., Slough, UK), consisting of a coil of 912 mL and 4.0 mm bore 144 
polyfluoroalkoxy (PFA) tubing. The revolution speed was adjusted with a controller to 1,200 145 
rpm. Fractions were collected with a Gilson FC202 fraction collector (Villiers-le-Bel, France). 146 
A preparative Knauer K-1800 HPLC pump (Berlin, Germany) was used to fill the HPCCC 147 
column with the stationary phase and pump the mobile phase. The effluent was continuously 148 
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monitored by a Knauer K-2501 spectrophotometer operating at 280 nm. Knauer EuroChrom 149 
software was used to record the chromatogram. The solvent system was composed of n-150 
hexane–ethyl acetate–methanol–water (4:5:4:5, v/v/v/v). The phase system was made up 151 
classically by vigorously shaking in a separating funnel and allowing the phases to equilibrate 152 
overnight.  The lower phase was separated and basified using NH3 (1% NH3 in lower phase, 153 
pH 8.7) to be used as a mobile phase. The sample solution was prepared by dissolving 500 mg 154 
of extract in 18 mL of equal volume of lower phase and upper phase of the solvent system 155 
selected for the separation. The resulting solution was filtered through a 0.45 μm PTFE 156 
membrane before use. The HPCCC column was initially filled with the upper phase 157 
(stationary phase). The apparatus was then rotated at 1,200 rpm, and the lower phase (mobile 158 
phase) was pumped into the column at a flow rate of 10 mL/min (reversed phase mode). After 159 
the mobile phase front emerged and hydrodynamic equilibrium was established, 18 mL of 160 
sample solution containing the crude extract (500 mg) was injected through the sample 161 
injection valve. The temperature of the apparatus was set at 30 °C. Fractions of 20 mL each 162 
were collected automatically for subsequent HPLC analysis. The retention of  the stationary 163 
phase was calculated according to a previously reported method [21]. 164 
 165 
2.4.2. Gel permeation chromatography 166 
The nostotrebin 6 fraction obtained by HPCCC was further cleaned-up by gel permeation 167 
chromatography (GPC) on Sephadex LH-20 (column length 31 cm, internal diameter 4 cm) 168 
with 50% methanol as eluent at a flow rate of 0.5 mL/min. Thirty-five fractions of 5 mL each 169 
were collected automatically and then evaporated under reduced pressure for subsequent off-170 
line HPLC-ESI-HRMS analysis. 171 
 172 
2.5. HPLC-ESI-HRMS 173 
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The analysis of the crude extract and the fractions obtained by HPCCC and GPC was 174 
performed on a A Dionex UltiMate 3000 HPLC system (Thermo Scientific, Sunnyvale, CA, 175 
USA) equipped with a diode array detector (DAD) and high resolution mass spectrometry 176 
with electrospray ionization source (ESI-HRMS; Impact HD Mass Spectrometer, Bruker, 177 
Billerica, MA, USA). The samples were subjected to a reversed phase column (Phenomenex 178 
Kinetex C18 column, 150 × 4.6 mm, 2.6 μm) at 30 °C. The mobile phase consisted of a 179 
combination of A (0.05% formic acid in acetonitrile, v/v) and B (0.05% formic acid in water, 180 
v/v). The gradient was as follows: 0–1 min, 85% B; 1–20 min, 85%–0% B; 20–25 min, 0% B; 181 
25–30 min, 0%–70% B, at a flow rate of 0.6 mL/min. The operating parameters of the mass 182 
spectrometer were as follows: the spray needle voltage was set at 3.5 kV, nitrogen was used 183 
both as nebulizing gas (2 bar) and drying gas (8 L/min), and the drying temperature was 200 184 
°C. The scanning range was 50–2,000 m/z and the scanning rate 1 Hz operating in the positive 185 
ion mode. The DAD was set at 280 nm to record the peaks, and the UV–Vis spectra were 186 
recorded from 200 to 650 nm. The chemical identity of the isolated compound was confirmed 187 
by comparing with the authentic standard of 99 % purity [16]. HPLC-ESI-HRMS was also 188 
used for the analysis of nostotrebin 6 uptake in bacterial samples. For this purpose, the 189 
previously reported experimental protocol was used [15]. 190 
 191 
2.6. Antimicrobial activity assay 192 
2.6.1. Bacterial strains 193 
Bacterial suspensions were prepared as follows. Bacterial strains were inoculated into blood 194 
agar and incubated for 24 hours at 35 °C. Four to five well-isolated colonies were dissolved in 195 
2 mL of Mueller Hinton broth (Himedia) and incubated for 2 hours at 35 °C. After that the 196 
broth was diluted in 10 mL of distilled water and used for testing of antimicrobial activity. In 197 
this study, the screening for the antimicrobial activity of nostotrebin 6 was performed against 198 
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Gram-positive (Enterococcus faecalis CCM 4224, Staphylococcus aureus CCM 4223 and 199 
Staphylococcus aureus CCM 3953) and Gram-negative (Escherichia coli CCM 3954 and 200 
Pseudomonas aeruginosa CCM 3955) reference bacterial strains from the Czech Collection 201 
of Microorganisms (CCM), Faculty of Science, Masaryk University Brno. Multidrug-resistant 202 
Gram-positive strains (fluoroquinolone-resistant Staphylococcus haemolyticus A/16568, 203 
methicillin-resistant Staphylococcus aureus MRSA 4591 and vancomycin-resistant 204 
Enterococcus faecium VanA 419/ana) and yeasts (Candida albicans 978, Candida tropicalis 205 
5 and Candida parapsilosis 6) from the culture collection of Department of Microbiology 206 
(Faculty of Medicine and Dentistry, Palacky University Olomouc) were also tested. All tested 207 
microorganisms were stored in cryotubes (ITEST plus, Czech Republic) at -80 °C. 208 
 209 
2.6.2. MIC assessment 210 
The antimicrobial efficacy of nostotrebin 6 was determined using the micro-dilution method, 211 
and the results were expressed as minimal inhibitory concentrations (MICs). Samples were 212 
diluted exponentially and tested in microtiter plates. Brain Heart Infusion broth (Himedia), 213 
Mueller Hinton broth (Himedia) and glucose-peptone broth (Oxoid) were used as cultivation 214 
medium for Gram-positive, Gram-negative bacteria and yeasts, respectively. Plates were 215 
inoculated into a standard quantity of microbe (106 CFU/mL). MIC was subtracted after 24 216 
and 48 hours for bacteria and yeast, respectively. 217 
 218 
2.6.3. Growth curves assessment 219 
This procedure was performed only with Gram-positive bacteria strains as they were 220 
significantly inhibited by nostotrebin 6. Stock solution of the compound was prepared in 221 
DMSO (c=50 mg/mL) and diluted in liquid cultivating medium to a concentration of 0.125 222 
mg/mL and then diluted exponentially in 96-well microtiter plate. The last row of wells was 223 
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used as a positive control of bacterial growth. The plate was subsequently inoculated with 224 
bacterial suspensions, covered with foil to stop evaporation and moved to a 225 
spectrophotometer with built-in incubator. Optical density (at 630 nm) was measured every 226 
hour over 24 hours and the measured values were used to construct growth curves. 227 
 228 
2.6. Statistical evaluation 229 
Three independent experiments were performed in three replicates for each sample if not 230 
stated otherwise. Data were expressed as mean ± standard deviation (S.D.), which was lower 231 
than 5 % and 7 % for growth curves assessment and cell uptake LC-MS analysis, 232 
respectively. MIC data are of non-continuous nature, based on three independent experiments 233 
measured in doublets, expressed as average value. All data and error bars were evaluated and 234 
plotted using Microsoft Office Professional Edition (ver. 11, 2003). 235 
 236 
3. Results and Discussion 237 
Nostotrebin 6 was bio-produced using Nostoc sp. Lukešová 27/97 strain, Fig. 1A. This 238 
cyanobacterial strain was previously selected based on high production efficiency of 239 
nostotrebin 6 [16]. After 14 days pre-cultivation step (Fig. 1B) a 100 L photobioreactor was 240 
used for production of appropriate, i.e. large-scale multi-gram, amount of the Nostoc sp. 241 
biomass (Fig. 1C). Consequently, cyanobacterial biomass was harvested, homogenized and 242 
extracted (Fig. 1D). Due to the emulsification properties hampering the HPCCC separation, 243 
polar lipids in the biomass extract had to be removed by precipitation in cold acetone. The 244 
resulting delipidated extract was directly used for isolation and purification of nostotrebin 6 245 
(Fig. 1E-F). 246 
Recently, nostotrebin 6 has been separated from cultivated soil cyanobacteria in a two-247 
step HPCCC operation [21]. This semi preparative HPCCC method combined isocratic and 248 
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gradient elution using a two-phase solvent system composed of n-hexane–ethyl acetate–249 
methanol–water (4:5:4:5, v/v/v/v), with the basic lower phase (1% NH3 in lower phase, pH 250 
8.7) employed as mobile phase [21]. In the present study, nostotrebin 6 was obtained from 251 
crude extract (Fig. 2A) by a preparative HPCCC method followed by gel permeation 252 
chromatography (GPC). The stationary phase retention accounted for the 80.82 % of the 253 
HPCCC column capacity. Nostotrebin 6 was identified in the HPCCC fraction eluted at a 254 
retention time (tR) between 35 and 42 min (Fig. 1E) at a purity of 45 % (Fig. 2B). This 255 
fraction was subjected to gel permeation chromatography (GPC) on Sephadex LH-20 (Fig. 256 
1F) to improve further its purity. As a result, nostotrebin 6 (20 mg) was obtained at purity 257 
96.5±0.2% as determined by HPLC-ESI-HRMS. Its identity was confirmed using by the 258 
presence of the protonated molecule at m/z 799 and main fragment ions at m/z 399.1, 371.1, 259 
343,1 and 307.0 as reported previously [16] (Fig. 2C). 260 
Using the described bio-production approach, ~50 g of Nostoc sp. strain biomass was 261 
prepared during 14 days cultivation period in a 100 L bioreactor, with very reproducible 262 
results. The gain of the crude extract was 16.6±3.0 % with respect to dry biomass. Further 263 
purification of nostotrebin 6 resulted in a yield of 4 % and 0.53±0.1% on the basis of crude 264 
extract and dried biomass, respectively. The purity evaluation was based on the HPLC-ESI-265 
HRMS methodology described in sec. 2.5. The procedure could be used for the easy-to-make 266 
isolation of multigram amounts of target molecule, which is crucial for its consequent 267 
biological testing, synthetic modifications and technological lab-scale applications. However, 268 
the real advantage of the approach described is the possibility of immediate and relatively 269 
easy transfer of this technology to a larger scale. 270 
 Preliminary data indicated that nostotrebin 6 is a bioactive substance affecting enzyme 271 
functions and cell proliferation [15, 16], which was also reported for many other CPDs [1]. 272 
Given that CPD structures were previously described as effective antibacterial agents [17-20], 273 
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the present study was focused on evaluation of nostotrebin 6 antibacterial action. The testing 274 
was based on a screening panel containing Gram-positive reference strains (Enterococcus 275 
faecalis CCM 4224, Staphylococcus aureus CCM 4223 and Staphylococcus aureus CCM 276 
3953), multidrug-resistant bacterial strains (Staphylococcus haemolyticus A/16568, 277 
Staphylococcus aureus MRSA 4591 and Enterococcus faecium VanA 419/ana), Gram-278 
negative reference strains (Escherichia coli CCM 3954 and Pseudomonas aeruginosa CCM 279 
3955) and yeasts (Candida albicans 978, Candida tropicalis 5, Candida parapsilosis 6). The 280 
antimicrobial and antifungal activities were tested using a standard micro-dilution method, 281 
and the results were expressed as minimal inhibitory concentrations (MICs). There was no 282 
effect on the growth of Gram-negative strains and yeasts in the concentration range from 1.95 283 
µg/mL to 1 mg/mL. Conversely, the nostotrebin 6 MIC values against Gram-positive bacteria 284 
varied from 6.25 to 15.6 µg/mL (Fig. 3A). The dynamic growth curve of Staphylococcus 285 
aureus MRSA 4591 in the presence of different nostotrebin 6 concentrations (Fig. 3B), shows 286 
unequivocally that nostotrebin 6 inhibits bacterial growth in a dose-dependent manner, 287 
exerting its effect even at the lowest concentration used in the test (1.95 µg/mL). 288 
Finally, we monitored nostotrebin 6 uptake into bacterial cells (Enterococcus faecalis 289 
CCM 4224 and Staphylococcus aureus CCM 3953) by HPLC-ESI-HRMS [15]. When 290 
increasing the concentration of nostotrebin 6, its accumulation can be observed in bacterial 291 
biomass (Fig. 3C). At a concentration around 4 µM (i.e. 3 µg/mL) the bacterial cells are 292 
saturated by nostotrebin 6, which corresponds well with strong inhibition of bacterial growth 293 
(Fig. 3A). 294 
The recognition of a molecular mechanism of nostotrebin 6 antibiotic activity is 295 
important for further research. However, our results indicate that nostotrebin 6 could be 296 
synthesized by cyanobacteria as a protective factor against biotic stress. The reason for this 297 
hypothetical statement is based on the fact that the cyanobacteria producing nostotrebin 6 are 298 
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Gram-negative type bacteria, but nostotrebin 6 is a growth inhibitor only against Gram-299 
positive ones. Thus, there is minimal self-toxicity for Gram-negative cyanobacteria producing 300 
nostotrebin 6, and simultaneously there is an antibiotic action against bacteria which are not 301 
cyanobacteria. For hypothesis confirmation, the results presented in this report have to be 302 
extended for consequent finding in the field of nostotrebin 6 biosynthesis and investigations 303 
of its antibiotic action at a molecular level. 304 
 305 
4. Conclusion 306 
A large-scale bio-production method aligned with the combined use of HPCCC and GPC 307 
enabled the isolation of nostotrebin 6 at over 96% purity. Nostotrebin 6 was shown to possess 308 
antibacterial activities against selected standard reference and multi-drug resistance strains of 309 
Gram-positive bacteria. As the nostotrebin 6 MICs values against multi-drug resistance strains 310 
varied from 6.25 to 15.6 µg/mL, this compound could serve as a basic nucleus for further 311 
design and synthesis of simplified CPD structures or for direct application as an antimicrobial 312 
product. The selectivity of nostotrebin 6 against Gram-positive bacteria supports its potential 313 
applicability, especially in biotechnological field, e.g. applications requiring Gram-positive 314 
bacteria elimination in presence of Gram-negative ones. The results presented here extend our 315 
knowledge in the field of antibiotic action of newly identified phenolic compounds [32, 33] 316 
and more specifically of CPDs [1] from cyanobacteria. 317 
318 
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Fig. 1. General procedure for Nostoc sp. Lukešová 27/97 biomass production and purification 422 
by HPCCC and GPC method. For detail description of panels (A-F) see the main text. 423 
Nostotrebin 6 (Nos-6) chemical structure (G). 424 
 425 
 426 




Fig. 2. Total ion HPLC-ESI-HRMS chromatograms of (A) Nostoc sp. Lukešová 27/97 crude 430 
extract, (B) nostotrebin 6 fraction obtained by HPCCC separation with retention time between 431 
35 and 42 min, and (C) nostotrebin 6 fraction obtained by HPCCC separation followed by gel 432 
permeation chromatography on Sephadex LH-20. (D) Positive-ion mass spectrum of 433 
nostotrebin 6 showing the protonated molecule and (E) corresponding MS2 spectrum. 434 
 435 
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 437 
A
Enterococcus faecalis CCM 4224 6.25
Staphylococcus aureus CCM 3953 6.25
Staphylococcus aureus CCM 4223 6.25
Enterococcus faecium VanA 419/ana* 6.25
Staphylococcus aureus MRSA 4591* 15.6
Staphylococcus haemolyticus A/16568* 12.5
MICs, nostotrebin 6 (µg/ml)
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Fig. 3. (A) Minimal inhibition concentrations (MICs) of nostotrebin 6 for selected Gram-440 
positive bacteria, (*) multi-resistant strains. MICs equal minimal bactericidal concentrations. 441 
(B) Growth curves for Staphylococcus aureus MRSA 4591 incubated with various 442 
concentrations of nostotrebin 6. (C) Nostotrebin 6 bacterial cell uptake, incubation period was 443 
4 h. Data are means ±SD of three independent experiments measured in triplicates. Error bars 444 
smaller than the plotted symbols are not visible. 445 
